They are currently engaged in a clinical stufy for their NAC, and beginning development of enhanced biologically derived grafts — capable of sustained drug delivery — to improve outcomes for third degree burn survivors through an NIH grant.

Nuro is making a headset and multimodal, multidirectional operating system (dubbed NUOS) to help a locked-in patients communicate with the world. Their headset is combining EEG and EOG into a set of algorithms that give stroke patients their independence and dignity back. You can view their current work on their website where they show patients communicating independently with just their brain – no voice, no touch. They are the only manufacturer in the world cleared by Health Canada, US IRB and US FDA under ‘Expanded Access’ for Communication by Brain for up to Locked-In Stage VI ALS. NURO has developed a complete neurological product line named NUOS, which can be implemented instantly without any brain surgery and with a wide range of individuals, from healthy human beings to victims of Stroke, Trauma or Neurodegeneration.

Intrinsic Medicine is a platform company innovative safe, bioactive sugars (like those HMOs) as a new therapeutic modality. With a combined 30 years of pharmaceutical industry experience at Ionis, Jason and Alex have been are using two key HMOs to be the only safe and effective solution for young people with irritable bowel syndrome, and they are taking their lead assets to clinical trial now.

Convalesce have developed a platform that enables hyperlocal cell reprogramming through advanced materials harboring genes and/or cells of interest in vivo. We have demonstrated that CNV platform’s ECM can provide robust cell survival (3X) in vivo and enhance targeted differentiation. We were also able to get 2.5X higher expression of a gene-of-interest. Convalesce is leveraging its platform initially to target eye disease, dry age related macular degeneration (AMD) and is raising series seed to complete pre-clinical development by 2022.

Filtricine developed a targeted nutrient deprivation (TND) therapy for treating a broad spectrum of cancer. This enables doctors and medical care professionals to exploit metabolic dependencies to stop the spread of cancer without the use of drug substances. The product now a two step cancer therapy, the first step is a meal plan that excludes the key nutrients, which the Filtricine team has shown to slow down drugs in 4 different cancer types. The second step is a dialysis with a formulated fluid that removes the targeted nutrients from the body. They have already completed pre-clinical studies to get FDA approval.

When time is of the essence, being able to screen potential therapies with your personalized cancer avatar in under 10 days is fast. Doing so with more accuracy than today’s sequencing or organoid approaches is huge. Through their growing list of strategic partnerships, OncoPrecision is screening, selecting, and speeding up the delivery of precision oncology.

Their device, MiniTC, has been shown to isolate fat-derived stem cells at in a disposable, closed loop medical device in any clinic setting, with no change in infrastructure. It’s fast gaining adoption in medical aesthetics, plastic and reconstructive surgeries, orthopedics and wound care. This platform is unlocking a therapeutic development program, their first program in clinical development, JTL-T-01, is a proprietary injectable stem cell biologic therapy for osteoarthritis, and is already approved under FDA’s 510k program.

Diadem Biotherapeutics is engineering a platform to decorate the outside of exosomes, so that they act as signaling molecules. By engineering the surface of exosomes, with signaling agonists, they can craete a new therapeutic modality, 10,000X more potent than the unattached protein. Moreover, they can engineer potent combinations of multiple receptor agonists. The team is currently performing IND-enabling studies for oncology and autoimmune disorders.